Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study The interplay between the human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback